Rubius Therapeutics (RUBY) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity
March 12, 2020 7:01 AM EDTRTX-240 Investigational New Drug Application for Solid Tumors Cleared by U.S. FDA
Internal cGMP Manufacturing Ready to Support Upcoming Oncology Clinical Trials
Cash Runway Extended into 2022
Conference Call Scheduled for Today at 8:00 a.m. EST
CAMBRIDGE, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY) a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported fourth quarter and... More
